Reduction of peripheral blood T cells producing IFN-γ and IL-17 after therapy with abatacept for rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 32, Issue 2, 2014, Pages 204-210

  Scarsi, Mirko ^a   Zanotti, Cinzia ^b   Chiarini, Marco ^b   Imberti, Luisa ^b   Piantoni, Silvia ^a   Frassi, Micol ^a   Tincani, Angela ^a   Airò, Paolo ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b AIL Research Laboratory Diagnostic Department Spedali Civili of Brescia   (Italy)

Author keywords

Abatacept; Interferon gamma (IFN ); Interleukin 17; Rheumatoid arthritis; T cells

Indexed keywords

ABATACEPT; C REACTIVE PROTEIN; CD28 ANTIGEN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GAMMA INTERFERON; INTERLEUKIN 17; METHOTREXATE; RHEUMATOID FACTOR; T LYMPHOCYTE RECEPTOR; AUTOANTIBODY;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY SCORE; DISEASE DURATION; FEMALE; FLOW CYTOMETRY; HUMAN; IN VITRO STUDY; LONGITUDINAL STUDY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; MALE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; TREATMENT FAILURE; ANTIBODY DETECTION; COHORT ANALYSIS; DAS28; DRUG EFFICACY; LYMPHOCYTE COUNT; MIDDLE AGED; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; IMMUNOCONJUGATES; INTERFERON-GAMMA; INTERFERON-GAMMA RELEASE TESTS; INTERLEUKIN-17; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84904752585     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. ACUTO O, MICHEL F: CD28-mediated costimulation: a quantitative support for TCR signalling. Nat Rev Immunol 2003; 3: 939-51.
2. LENSCHOW DJ, WALUNAS TL, BLUESTONE JA: CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996; 14: 233-58.
3. YING H, YANG L, QIAO G et al.: CTLA-4-B7 interaction suppresses Th17 cell differentiation. J Immunol 2010; 185: 1375-8.
4. CUTOLO M, NADLER SG: Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis. Autoimmun Rev 2013; 12: 758-67.
5. AXMANN R, HERMAN S, ZAISS M et al.: CTLA-4 directly inhibits osteoclast formation. Ann Rheum Dis 2008; 67: 1603-9.
6. MARTI L, GOLMIA R, GOLMIA AP et al.: Alterations in cytokine profile and dendritic cells subsets in peripheral blood of rheumatoid arthritis patients before and after biologic therapy. Ann N Y Acad Sci 2009; 1173: 334-42.
7. BUCH MH, BOYLE DL, ROSENGREN S et al.: Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis 2009; 68: 1220-7.
8. CUTOLO M, SOLDANO S, MONTAGNA P et al.: CTLA4-Ig interacts with cultured synovial macrophages from rheumatoid arthritis patients and downregulates cytokine production. Arthritis Res Ther 2009; 11: R176.
9. WENINK MH, SANTEGOETS KC, PLATT AM et al.: Abatacept modulates proinflammatory macrophage responses upon cytokineactivated T cell and Toll-like receptor ligand stimulation. Ann Rheum Dis 2012; 71: 80-3.
10. KOENDERS MI, MARIJNISSEN RJ, JOOSTEN LAB et al.: T cell lessons from the rheumatoid arthritis synovium SCID mouse model. CD3-rich synovium lacks response to CTLA-4Ig but is successfully treated by interleukin-17 neutralization. Arthritis Rheum 2012; 64: 1762-70.
11. AIRÒ P, SCARSI M: Targeting CD4+CD28-T cells by blocking CD28 co-stimulation. Trends Mol Med 2013; 19: 1-2.
12. SCARSI M, ZIGLIOLI T, AIRÒ P: Decreased circulating CD28-negative T cells in patients with rheumatoid arthritis treated with abatacept are correlated with clinical response. J Rheumatol 2010; 37: 911-6.
13. STRIOGA M, PASUKONIENE V, CHARACIEJUS D: CD8+ CD28-and CD8+ CD57+ T cells and their role in health and disease. Immunology 2011; 134: 17-32.
14. SCHMIDT D, GORONZY JJ, WEYAND CM: CD4+ CD7-CD28-T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity. J Clin Invest 1996; 97: 2027-37.
15. PAWLIK A, OSTANEK L, BRZOSKO I et al.: The expansion of CD4+CD28-T cells in patients with rheumatoid arthritis. Arthritis Res Ther 2003; 5: R210-3.
16. ZHENG Y, MANZOTTI CN, LIU M, BURKE F, MEAD KI, SANSOM DM: CD86 and CD80 differentially modulate the suppressive function of human regulatory T cells. J Immunol 2004; 172: 2778-84.
17. WELLS G, BECKER J-C, TENG J et al.: Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009; 68: 954-60.
18. Van GESTEL AM, HAAGSMA CJ, van RIEL PL: Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998; 41: 1845-50.
19. SCARSI M, ZIGLIOLI T, AIRÒ P: Baseline numbers of circulating CD28-negative T cells may predict clinical response to abatacept in patients with rheumatoid arthritis. J Rheumatol 2011; 38: 2105-11.
20. LIU W, PUTNAM AL, XU-YU Z et al.: CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006; 203: 1701-11.
21. PELCHEN-MATTHEWS A, PARSONS IJ, MARSH M: Phorbol ester-induced downregulation of CD4 is a multistep process involving dissociation from p56 lck, increased association with clathrin-coated pits, and altered endosomal sorting. J Exp Med 1993; 178: 1209-22.
22. PIEPER J, HERRATH J, RAGHAVAN S, MUHAMMAD K, VANVOLLENHOVEN R, MALMSTRöM V: CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients. BMC Immunology 2013; 14: 34.
23. KAWASHIMA M, MIOSSEC P: Effect of treatment of rheumatoid arthritis with infliximab on IFN gamma, IL4, T-bet, and GATA-3 expression: link with improvement of systemic inflammation and disease activity. Ann Rheum Dis 2005; 64: 415-8.
24. SMOLEN JS, ALETAHA D: Forget personalized medicine and focus on abating disease activity. Ann Rheum Dis 2013; 72: 3-6.
25. ARAVENA O, PESCE B, SOTO L et al.: Anti-TNF therapy in patients with rheumatoid arthritis decreases Th1 and Th17 cell populations and expands IFN-?-producing NK cell and regulatory T cell subsets. Immunobiology 2011; 2161256-63.
26. AERTS NE, EBO DG, BRIDTS CH, STEVENS WJ, De CLERCK LS: T cell signal transducer and activator of transcription (STAT) 4 and 6 are affected by adalimumab therapy in rheumatoid arthritis. Clin Exp Rheumatol 2010; 28: 208-14.
27. SZALAY B, VáSáRHELYI B, CSEH A et al.: The impact of conventional DMARD and biological therapies on CD4+ cell subsets in rheumatoid arthritis: a follow-up study. Clin Rheumatol 2013 Aug 11 [Epub ahead of print].
28. PAWLIK A, OSTANEK L, BRZOSKO I et al.: Therapy with infliximab decreases the CD4+CD28-T cell compartment in peripheral blood in patients with rheumatoid arthritis. Rheumatol Int 2004; 24: 351-4.
29. BRYL E, VALLEJO AN, MATTESON EL, WITKOWSKI JM, WEYAND CM, GORONZY JJ: Modulation of CD28 expression with antitumor necrosis factor alpha therapy in rheumatoid arthritis. Arthritis Rheum 2005; 52: 2996-3003.
30. KORMENDY D, HOFF H, HOFF P, BROKER BM, BURMESTER GR, BRUNNER-WEINZIERL MC: Impact of the CTLA-4/CD28 axis on the processes of joint inflammation in rheumatoid arthritis. Arthritis Rheum 2013; 65: 81-7.
31. YAMADA H, NAKASHIMA Y, OKAZAKI K et al.: Preferential accumulation of activated Th1 cells not only in rheumatoid arthritis but also in osteoarthritis joints. J Rheumatol 2011; 38: 1569-75.
32. SALLUSTO F, LENIG D, FORSTER R, LIPP M, LANZAVECCHIA A: Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401: 708-12.
33. KANBE K, CHIBA J, NAKAMURA A: Immunohistological analysis of synovium treated with Abatacept in rheumatoid arthritis. Rheumatol Int 2013; 33: 1883-7.
34. SFIKAKIS PP, ZOGRAFOU A, VIGLIS V et al.: CD28 expression on T cell subsets in vivo and CD28-mediated T cell response in vitro in patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 649-54.
35. FASTH AE, SNIR O, JOHANSSON AA et al.: Skewed distribution of proinflammatory CD4+CD28null T cells in rheumatoid arthritis. Arthritis Res Ther 2007; 9: R87.
36. SAMSON M, AUDIA S, JANIKASHVILI N et al.: Inhibition of IL-6 function corrects Th17/ Treg imbalance in rheumatoid arthritis patients. Arthritis Rheum 2012; 64: 2499-503.
37. YUE C, YOU X, ZHAO L et al.: The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis patients. Rheumatol Int 2010; 30: 1553-7.
38. LI Y, JIANG L, ZHANG S et al.: Methotrexate attenuates the Th17/IL-17 levels in peripheral blood mononuclear cells from healthy individuals and RA patients. Rheumatol Int 2012; 32: 2415-22.
39. COLIN EM, ASMAWIDJAJA PS, van HAMBURG JP et al.: 1,25-dihydroxyvitamin D3 modulates Th17 polarization and interleukin-22 expression by memory T cells from patients with early rheumatoid arthritis. Arthritis Rheum 2010; 62: 132-42.
40. ÁLVAREZ-QUIROGA C, ABUD-MENDOZA C, DONíZ-PADILLA L et al.: CTLA-4-Ig therapy diminishes the frequency but enhances the function of Treg cells in patients with rheumatoid arthritis. J Clin Immunol 2011; 31: 588-95.
41. HUANG Z, YANG B, SHI Y et al.: Anti-TNF-α therapy improves Treg and suppresses Teff in patients with rheumatoid arthritis. Cell Immunol 2012; 279: 25-9.
42. PESCE B, SOTO L, SABUGO F et al.: Effect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patients. Clin Exp Immunol 2013; 171: 237-42.
43. VALENCIA X, STEPHENS G, GOLDBACHMANSKY R, WILSON M, SHEVACH EM, LIPSKY PE: TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 2006; 108: 253-61.
44. PLATT AM, GIBSON VB, PATAKAS A et al.: Abatacept limits breach of self-tolerance in a murine model of arthritis via effects on the generation of T follicular helper cells. J Immunol 2010; 185: 1558-67.